94265-41-5

Basic information

• Product Name: 2-(2,4,6-Trimethyl-phenyl)-ethyl-p-toluolsulfonat
• Synonyms: 2-(2,4,6-Trimethyl-phenyl)-ethyl-p-toluolsulfonat
• CAS NO: 94265-41-5
• Molecular Weight: 318.437
• Mol File: 94265-41-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(2,4,6-Trimethyl-phenyl)-ethyl-p-toluolsulfonat(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,4,6-Trimethyl-phenyl)-ethyl-p-toluolsulfonat(94265-41-5)
• EPA Substance Registry System: 2-(2,4,6-Trimethyl-phenyl)-ethyl-p-toluolsulfonat(94265-41-5)

Safety Data

• Hazardous Substances Data: 94265-41-5(Hazardous Substances Data)

Upstream product

• 6950-92-1 2-(2,4,6-trimethylphenyl)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 41841-19-4 methyl 2-mesitylacetate 
• 4408-60-0 2-mesitylacetic acid 

Downstream Products

• 1208109-83-4 1'-(2-mesitylethyl)-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 769-25-5 2,4,6-trimethylstyrene 
• 91763-52-9 2-(2-methoxyethyl)-1,3,5-trimethylbenzene 

Relevant articles and documents

Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-ones as potassium-competitive acid blockers

With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-one derivatives, which could occupy two important lipophilic pockets (described as LP-1 and LP-2) of H+,K+-ATPase and can strongly bind to the K+-binding site, were designed based on a docking model. Among the compounds synthesized, compound 4d showed a strong H+,K+-ATPase-inhibitory activity and a high stomach concentration in rats, resulting in potent inhibitory action on histamine-stimulated gastric acid secretion in rats. Furthermore, 4d exerted significant inhibitory action on histamine-stimulated gastric-acid secretion in rats with a rapid onset and moderate duration of action after the administration. These findings may lead to a new insight into the drug design of potassium-competitive acid blockers.